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RESUMO
Eficácia e segurança do levosimendam 
na prática clínica
Indrodução: em estudos randomizados prévios, 
o levosimendan melhorou a evolução clínica 
e o estado hemodinâmico dos doentes, com 
um efeito prognóstico ainda não totalmente 
esclarecido. existem, contudo, poucos dados 
relativos aos seus efeitos clínicos, quando 
usado na prática diária.
Objectivo: Avaliámos a eficácia clínica e a 
segurança do levosimendam no tratamento 
da insuficiência cardíaca aguda sistólica em 
condições de prática clínica diária.
Métodos: Neste estudo prospectivo, 
multicêntrico e não randomizado, foi 
administrada uma perfusão contínua de 
levosimendam (0,05 μg/Kg/min-0,2 μg/Kg/
min) durante 24 horas. Foi administrado 
um bólus de 12 μg/Kg durante 10 minutos 
de forma opcional. O objectivo primário 
combinado de eficácia clínica (definido 
por uma pontuação de oito variáveis) e de 
segurança (definido pela ausência de efeitos 
adversos graves) foi avaliado às 24 horas após 
o início do tratamento; um segundo objectivo 
primário combinado similar foi avaliado aos 
cinco dias de tratamento.
Resultados: Foram recrutados 129 doentes 
consecutivos que necessitavam de fármacos 
inotrópicos apesar da terapêutica optimizada 
ABSTRACT
Background: In previous randomized studies 
levosimendan improved hemodynamics and 
clinical course, with a still unclear effect 
on prognosis. there are, however, few data 
regarding its effects when used in daily 
practice.
Aims: We evaluated the clinical effectiveness 
and safety of levosimendan in the treatment 
of acute systolic heart failure (SHF) in daily 
practice conditions.
Methods: In this prospective, multicenter, 
nonrandomized trial, a continuous infusion of 
levosimendan (0.05 μg/kg/min-0.2 μg/kg/min) 
was administered for 24 hours. An optional 
loading dose of 12 μg/kg over 10 minutes 
was used. the primary combined endpoint of 
clinical effectiveness (as defined by a eight-
variable clinical score) and safety (defined by 
the absence of serious adverse events) was 
assessed at 24 hours after the beginning of 
treatment; a second similar primary combined 
endpoint was assessed at 5 days.
Results: One hundred and twenty-nine 
consecutive patients requiring inotropes 
despite optimal oral background heart failure 
therapy were recruited. the primary endpoint 
was reached in 80.6% at 24 hours and in 
79.7% at 5 days. During the six months before 
levosimendan the number of patient days of 
hospitalization for heart failure was 14.9±14.6 
versus 3.1±7.6 during the six months 
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supply/consumption balance is not disturbed(7,8). 
Several recent randomized studies have ad-
dressed the clinical effects of levosimendan(9-13). 
In the ReVIVe study it improved the clinical 
course, compared to placebo, in patients 
with worsening heart failure(9), in the LIDO 
study levosimendan improved hemodynamic 
performance more effectively than dobutamine 
in patients with severe low-output heart 
failure(10). In the RuSSLAN study levosimendan, 
as compared to placebo, did not increase the 
incidence of clinically significant hypotension or 
of myocardial ischemia (in doses up to 0.2 μg/
kg/min, although higher doses did) in patients 
with left ventricular failure complicating an 
acute myocardial infarction(11). In the latter two 
studies and also in CASINO(12) levosimendan 
reduced six-month mortality(10,11), although this 
was not seen when the drug was compared with 
dobutamine in acute decompensated heart failure 
in the SuRVIVe study(13). there are, however, 
few data regarding its clinical effectiveness 
and safety in an everyday clinical setting. We 
therefore conducted the Portuguese Study 
on the tolerability, Safety and effectiveness 
of Levosimendan in Daily Clinical Practice 
(PORtLAND) to test the hypothesis that in day-
to-day practice, under less controlled conditions 
INTRODUCTION
Inotropic agents are indicated in acute heart failure with systolic dysfunction in the presence 
of peripheral hypoperfusion (hypotension, 
decreased renal function) with or without 
congestion or pulmonary edema refractory to 
diuretics and vasodilators at optimal doses(1,2). 
However, concern exists regarding a possible 
negative impact on prognosis caused by inotropes 
acting through the adrenergic pathway(3-5), since 
they may induce ventricular arrhythmias and 
myocardial ischemia(6). these negative effects 
may be linked to levels of cytoplasmic calcium 
and cyclic-AMP concentrations since adrenergic 
agonists result in an abundance of these signaling 
molecules(3-5). In addition, negative prognosis 
following administration of adrenergic agonists, 
i.e. traditional inotropes, may be correlated with 
a disturbance of the myocardial oxygen supply/
consumption balance(3,6-8). Levosimendan acts 
through different mechanisms(6-8): it increases 
cardiac contractility by enhancing the sensitivity 
of troponin C to calcium, and produces vaso-
dilatation through the opening of AtP-sensitive 
potassium channels(6-8). Levosimendan does not 
increase cytoplasmic calcium or cyclic-AMP 
concentrations and the myocardial oxygen 
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para a insuficiência cardíaca. O objectivo 
primário foi atingido em 80,6% às 24 horas 
e em 79,7% aos cinco dias. A média de dias 
de hospitalização por doente nos seis meses 
precedentes ao uso de levosimendam foi de 
14.9±14.6 versus 3.1±7.6 dias nos meses 
subsequentes ao seu uso (p<0,001).
Conclusões: Na prática clínica diária, o 
levosimendam foi eficaz e seguro em 80,6% e 
79,7% dos doentes com insuficiência cardíaca 
sistólica aguda às 24 horas e aos 5 dias, 
respectivamente, após o início do tratamento. 
também ocorreu uma redução marcada do 
número de dias de hospitalização nos seis 
meses subsequentes. 
Palavras-Chave
Insuficiência cardíaca aguda; Inotrópicos; Levosimendam
following levosimendan (p<0.001).
Conclusions: In daily practice, levosimendan 
was clinically effective and safe in 80.6% and 
79.7% of patients with acute SHF at 24 hours 
and 5 days respectively after the beginning of 
treatment. A marked reduction in the number 
of days of hospitalization for heart failure was 
also seen during the subsequent six months.
Key words 
Acute heart failure; Inotropes; Levosimendan
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Study protocol. the treatment with 
levosimendan started with an optional loading 
dose of 12 μg/kg for 10 minutes and was followed 
by a continuous infusion of 0.05 μg/kg/min, 0.1 
μg/kg/min or 0.2 μg/kg/min of levosimendan for 
24 hours, via a peripheral or central vein(11). the 
decision to administer or withhold the loading 
dose, and the choice of the maintenance dose, 
were at the discretion of the investigators, based 
on their clinical assessment of the patients. An 
initial maintenance dose of 0.1 μg/kg/min was 
suggested; if after 30 to 60 minutes the response 
was considered excessive, due to the occurrence 
of tachycardia or hypotension, it was suggested 
that the dose be reduced to 0.05 μg/kg/min; if the 
effects persisted, the drug could be discontinued; 
in the event of hypotension persisting despite 
discontinuation of levosimendan, in principle 
the drug should not be replaced by another with 
a similar hemodynamic profile (for example 
dobutamine or a phosphodiesterase inhibitor 
[PDeI]); if the patient was dehydrated, a 
saline infusion was suggested. Only in cases of 
marked hypotension (systolic blood pressure 
<80 mmHg) or of less severe but symptomatic 
hypotension was ACeI or beta-blocker therapy 
modified and/or vasopressors, such as dopamine 
or norepinephrine, administered; in such 
circumstances invasive hemodynamic monitoring 
would be considered(11). If the initial maintenance 
dose was well tolerated and a greater hemodynamic 
effect was desired, increasing to 0.2 μg/kg/min 
could be considered(11).
After the administration of levosimendan 
the patients underwent clinical, hematological, 
biochemical, urinary output and continuous 
eCG monitoring, together with noninvasive 
assessment of blood pressure, for a suggested 
period of 72 hours. Oximetric monitoring was 
also recommended. Invasive monitoring was not 
required.
Assessments. the patients were evaluated at 
baseline (before starting levosimendan) and at 24 
hours and 5 days after the start of levosimendan. 
Further visits were performed at 3 months and 
at the end of the six-month follow-up. Baseline 
evaluation included medical history and physical 
examination, eCG and 2D echocardiogram 
and blood sampling for assessment of standard 
laboratory variables as detailed elsewhere(11). 
At 24 hours and 5 days symptoms and signs 
of heart failure were assessed, adverse events, 
than those of the above studies, levosimendan 
is both effective and safe for the treatment of 
systolic acute heart failure. 
METHODS
Patients. this prospective, multicenter, 
nonrandomized clinical trial was performed in 
the intensive care units of 15 departments of 
cardiology or internal medicine(14).
eligible patients were those admitted to 
hospital with NYHA functional class III-IV heart 
failure, left ventricular ejection fraction ≤0.40 
and evidence of decompensation (as documented 
by the presence of pulmonary or systemic 
congestion, or symptoms and signs of low cardiac 
output, despite maximally tolerated oral therapy) 
which in the investigator’s opinion would require 
treatment with inotropes. At screening patients 
should be taking an angiotensin-converting 
enzyme inhibitor (ACeI) or an angiotensin-II 
receptor antagonist (ARB), unless contraindicated 
or not tolerated, and optimal oral therapy for 
heart failure which could include beta-blockers, 
diuretics, digoxin and spironolactone.
Criteria for exclusion were: shock or marked 
hypotension (systolic blood pressure <85 
mmHg) not responsive to intravenous fluids; 
significant uncontrolled tachyarrhythmia (rapid-
response atrial fibrillation/flutter, supraventricular 
tachycardia, ventricular tachycardia); resting or 
post-infarction angina; documented history of 
torsades de pointes; mechanical obstruction of 
ventricular filling or ejection; severe renal failure 
of non-prerenal cause (serum creatinine >3 mg/
dl); significant liver damage (liver transaminases 
three times above the upper normal limit) and/
or liver failure (prothrombin time three seconds 
above the upper normal limit in the absence 
of anticoagulant therapy); hypokalemia (serum 
potassium <3.5 mEq/L) not responsive to 
potassium supplements; significant anemia 
(serum hemoglobin <9 g/dl); pregnancy or breast-
feeding; hypersensitivity to levosimendan or any 
of its excipients.
the investigation conforms with the principles 
outlined in the Declaration of Helsinki (Br Med 
J 1964;ii:177). the study protocol was reviewed 
and approved by the ethics Committee of each 
participating institution and all patients gave 
their informed consent.
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as all other parameters remained unchanged(11). 
the safety of levosimendan was established by 
the absence of any serious adverse event with 
a probable or undetermined causal relationship 
with the drug.
In order to evaluate the primary combined 
endpoint the patients were distributed in a 
2x2 table according to the treatment outcome 
in relation to clinical effectiveness and safety 
(Table II). Achievement of the primary endpoint 
was calculated by the frequency in cell A.
Table II Distribution of patients according to treatment 
outcome in relation to safety and clinical effectiveness 
Safety
Without SAe With SAe
Clinical 
effectiveness
Clinical improvement A D
No clinical change B e
Clinical deterioration C F
SAe: serious adverse event with a probable or undetermined causal relationship 
with levosimendan
Prospectively defined secondary endpoints 
were changes from baseline to 24 hours and 
from baseline to 5 days in: NYHA functional 
class; patient self-evaluation symptom class 
(see definitions below); body weight; pulmonary 
congestion (see definitions below); previous 24-
hour diuresis; serum creatinine; oral medication 
for heart failure; and intravenous medication for 
heart failure. Additional secondary endpoints 
were: tolerability of levosimendan (defined 
by occurrence of adverse effects); safety of 
levosimendan (defined by occurrence of serious 
adverse events with a probable or undetermined 
causal relationship with levosimendan); the 
number and length of hospital readmissions due 
to heart failure during the six months following 
levosimendan (compared with the six months 
prior to treatment).
Definitions. In order to establish a classific-
ation of patient self-evaluation the patients were 
simply asked “How do you feel?” (no prompting 
was given) and the answer was classified as 
follows: class 1 – very well; class 2 – well; class 
3 – reasonable; class 4 – poorly; class 5 – very 
poorly. The presence of rales over the lung fields 
detected by auscultation was used to classify 
pulmonary congestion as follows: class 0 – 
none; class 1 – present in the basal third of the 
pulmonary fields; class 2 – present in two thirds; 
class 3 - present in three thirds.
Statistical analysis. Quantitative variables 
concomitant medication and previous 24-hour 
urinary output were recorded, and an eCG and 
blood analysis were performed; arrhythmia 
alarms and heart rate and blood pressure trends 
of the previous 24 hours were also reviewed(11). 
the number and length of hospital readmissions 
and mortality were recorded at three- and six-
month evaluations(11).
Study endpoints. the proportion of patients 
in whom levosimendan was both clinically 
effective and safe at 24 hours after the initiation of 
the infusion was one of the two primary endpoints 
of the study; the second primary endpoint was 
the proportion of patients in whom both clinical 
effectiveness and safety were observed at 5 days 
after the initiation of levosimendan infusion.
A score incorporating two subjective and 
six objective parameters assessed clinical 
effectiveness. Table I lists these parameters and 
the assessment criteria for each at 24 hours and 
at 5 days versus baseline values. Levosimendan 
was considered to have produced clinical 
improvement, i.e. was effective, when there was 
improvement in one or more group I (subjective) 
parameters, accompanied by improvement in one 
or more group II (objective) parameters, as long 
Group I – subjective parameters 
 Improvement No change Worsening
NYHA functional class i≥1 class fg h ≥1 class
Patient self-evaluation i≥1 class fg h ≥1 class
Group II – objective parameters
 Improvement No change Worsening
Body weight i≥1 kg fg h ≥1 kg
Pulmonary congestion i ≥1 class fg h ≥1 class
Previous 24-hour urine h ≥20% fg i ≥20%
output 
Serum creatinine  i ≥0.1 mg/dl fg h ≥0.1 mg/dl 
Oral HF medication Initiation of 
 ACeI or BB fg ---
IV HF medication Suspension of  fg 
 inotrope or   
 vasopressor or i of
 its previous dose
  
ACEI: angiotensin-converting enzyme inhibitors; BB: beta-blockers; HF: heart 
failure; IV: intravenous;h: increase; fg: unchanged; i: decrease
1- Addition of inotrope 
or vasopressor or h of its 
previous dose.
2- Need for hemodynamic 
or ventilatory mechanical 
support.
3- Initiation of iv 
diuretics more than 
72 hours after start of 
levosimendan
Table I Assessment criteria for clinical parameters used to 
evaluate clinical effectiveness of the treatment at 24 hours 
and 5 days versus baseline.
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Nitrates 47%
IV inotropes (total) 19%
Dobutamine alone 8%
Dopamine alone 8%
Dobutamine in combination with dopamine 3%
Data are presented as mean value ±SD.
ACeI: angiotensin-converting enzyme inhibitors; ARB: angiotensin receptor 
antagonists; HF: heart failure; IV: intravenous; NYHA: New York Heart 
Association.
Levosimendan infusion. Levosimendan 
was used in 104 (81%) patients as first line 
therapy, in 16 (12%) to substitute other ongoing 
inotropes and in nine (7%) in combination with 
other inotropes. No invasive monitoring was 
performed in 61% of cases. In 35% of the patients 
no loading dose of levosimendan was used, 
due to baseline systolic blood pressure values 
approaching 85 mmHg or to a baseline clinical 
status that, in the investigators’ opinion, did not 
require a rapid peak of levosimendan at the cost 
of the risk of hypotension. the maintenance 
dose was 0.05 μg/kg/min in 16%, 0.1 μg/kg/
min in 71% and 0.2 µg/kg/min in 13% of the 
patients (Figure 1). the mean maintenance dose 
was 0.1±0.04 μg/kg/min. Only eight (6%) did not 
complete the 24-hour infusion, with six of these 
cases due to hypotension.
Endpoints. the primary combined endpoint 
of clinical effectiveness and safety was reached 
in 104 (80.6%) of 129 patients (95% CI: 73.8%-
87.4%) at 24 hours and in 102 (79.7%) of 128 
patients (95% CI: 73.2%-87.1%) at 5 days; in 
one patient information regarding the primary 
endpoint at 5 days was not available.
(continuous and discrete) were described by 
calculating the frequency of observations (n), 
means and standard deviation. they were 
compared between groups using the Student’s t 
test adjusted for paired samples or the Wilcoxon 
non-parametric test when the hypothesis of 
normality was rejected. this was analyzed using 
the Shapiro-Wilks test. the tests were two-
tailed, with a level of significance of five percent. 
Qualitative variables (ordinal and nominal) 
were described by calculating the frequency 
of observations (n) and relative frequency (%). 
Ordinals were compared using the Wilcoxon 
non-parametric test. Nominals were analyzed by 
the McNemar test for paired samples. the tests 
were two-tailed, with a level of significance of 
five percent. A Kaplan-Meier curve was used to 
describe the distribution of time to death from 
any cause in the six months following treatment 
with levosimendan.
RESULTS
Clinical characteristics. A total of 129 
consecutive patients were enrolled between 
November 15 2001 and December 31 2003. 
Baseline characteristics are summarized in Table 
III. At baseline 66% of the patients were taking 
iv diuretics and 47% were taking nitrates.
Table III Baseline characteristics of the patients.
Number of patients 129
Age (yr) 63±14
Gender (male/female) 76%/24%
Cause of acute heart failure: ischemic/other 48%/52%
Acute decompensation of chronic heart failure 81%
Acute de novo heart failure 19% 
Number of HF admissions per patient during  2±1.2
the previous year 
NYHA functional class III/IV 19%/81%
Left ventricular ejection fraction (%) 24±7
Systolic blood pressure (mmHg) 104±17
Diastolic blood pressure (mmHg) 64±14
Heart rate (beats/min) 86±18 
Serum creatinine (mg/dl) 1.54±0.66
Serum sodium (mEq/l) 135±6.0
ACeI/ARB 92%
Beta-blockers 45%
Spironolactone 58%
Digitalis 58%
Oral diuretics (other than furosemide) 22%
IV diuretics 66%
Figure 1. Maintenance dose of levosimendan infusion.
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occurred in eight (6%) patients (Table V) during 
the first 5 days of follow-up: in 5 (63%) cases they 
consisted of hypotension that was considered 
sufficiently severe to endanger the patient’s life 
and thus required therapy. All these cases of 
severe hypotension resolved favorably.
During the first 5 days of follow-up heart rate 
did not increase (Table VI), nor did the incidence 
of supraventricular arrhythmias, or nonsustained 
ventricular tachycardias (Table VII). Qtc interval 
showed no significant change during this period; 
at 24 hours, but not at 5 days, serum potassium 
levels were lower than at baseline; serum 
hemoglobin showed a modest decrease during 
the first 5 days of follow-up (Table VI).
During the first 24 hours we observed a 
decrease in systolic blood pressure (SBP) (Table 
VI) and an increase in the incidence of significant 
hypotensive episodes (SBP <80 mmHg for more 
than three minutes) (Table VII). Only two of 
these were symptomatic (dizziness and syncope). 
In the majority of the significant hypotensive 
episodes no therapy was needed; levosimendan 
was withdrawn in six of these patients, in five of 
whom an iv saline infusion was initiated; in four 
cases dopamine or norepinephrine were used. 
All significant hypotension episodes resolved 
favorably. the excess in hypotensive episodes 
disappeared after day 1 (Table VII) and systolic 
During the first 24 hours after the initiation 
of levosimendan there was a rapid increase 
in diuresis (urine output = 2512±1107 ml) in 
formerly oliguric patients and a fall in serum 
creatinine levels that was maintained at day 5 
(Table IV). A consistent improvement in each 
of the individual subjective and objective 
parameters used to evaluate clinical effectiveness 
was observed at 24 hours and at 5 days compared 
to baseline (Table IV). As a consequence, due to 
the improvement in clinical condition, at 24 hours 
after the initiation of levosimendan 27 (20.9%) 
patients showed an improvement in therapy 
profile, as defined in Table I: 19 of the 25 (76%) 
patients receiving inotropes at baseline were no 
longer receiving these drugs at 24 hours; despite 
the baseline severity of acute heart failure and the 
fact that at baseline 92% of patients were already 
taking an ACeI/ARB, and 45% were taking a 
beta-blocker, at 24 hours these drugs had been 
initiated in an additional 11 (8.5%) patients 
(three of whom belonged to the previous group 
of 19 that had stopped inotropes). At 24 hours 
there was no change in the number of patients on 
iv diuretics compared to baseline (p=0.180) and 
fewer patients were taking iv nitrates compared 
to baseline (p=0.008).
Severe adverse events with a probable or 
uncertain causal relationship to levosimendan 
Table IV Clinical effectiveness of the treatment: improvement in subjective and objective parameters observed at 24 
hours and at 5 days compared to baseline.
 Baseline 24 hours p 5 days p
NYHA functional class 3.8±0.5 3.1±0.7 p<0.001 2.7±0.8 p<0.001
Patient self-evaluation class 4.5±0.6 3.5±0.9 p<0.001 2.9±1.1 p<0.001
Body weight (kg) 69.5±11.0 67.9±10.9 p<0.001 67.3±10.7 p<0.001
Pulmonary congestion class 1.2±0.8 0.6±0.6 p<0.001 0.4±0.6 p<0.001
Previous 24-hour urine output (ml) 1482.0±817.1 2512.0±1106.8 p<0.001 1947.2±1050.1 p=0.001
Serum creatinine (mg/dl) 1.54±0.66 1.44±0.67 P=0.001 1.41± 0.64 p=0.009
NYHA: New York Heart Association.
Table V Severe adverse events with a probable or uncertain causal relationship with levosimendan during the first 5 days 
of follow-up
Type of SAE Number of patients with SAE  Relationship of SAE with levosimendan 
Severe hypotension 5 Probable: 3 cases. Uncertain: 2 cases 
Severe hypokalemia 1 Probable
Ventricular fibrillation 1 Uncertain
Worsening of HF+VF 1 Uncertain
HF: heart failure; SAE: Serious adverse event with a probable or undetermined causal relationship with levosimendan; VF: ventricular fibrillation
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the percentage of patients who died or 
received heart transplants was 21% and 
29% at 3 months and six months of follow-up 
respectively.
DISCUSSION
The need for observational studies. 
there is frequently a delay of several years 
before the positive results of randomized clinical 
trials (RCts) are translated into routine clinical 
practice(15). Among other reasons, this probably 
stems from the fact that clinicians often feel 
that the non-selected patients they deal with 
in everyday practice are not comparable to the 
highly selected populations of clinical studies(16-
18). Although these trials have led to major 
advances in the treatment of heart failure, some 
authors believe that we should nevertheless 
recognize their limitations(16-18). these relate to 
the rigorous selection of the patients included 
and therefore in these authors’ opinion studies 
involving patients who are more typical of those 
encountered in routine practice are required(16-
18). Another important issue is the so-called 
external validity of RCts, that is, whether or not 
their results apply to a similar population in the 
community(19). Apparently this is not always the 
case(19). One explanation is that patients included 
blood pressure at day 5 was similar to that at 
baseline (Table VI). the number of patients 
presenting angina did not increase significantly 
during the initial 5 days of follow-up (Table VII). 
Only one patient had a new onset of angina: 
this was a post-myocardial infarction angina, 
occurring at day four after levosimendan, which 
was reported by the investigators as unlikely to 
be related to the drug administration.
the median duration of the index hospital-
ization (when levosimendan was administered) 
was six days (minimum two and maximum 60 
days), three of which were in intensive care units 
(minimum one and maximum 24 days). In 77% 
of patients the index hospitalization was less 
than ten days.
Comparing the six months before with the 
six months after the initiation of levosimendan 
therapy (in patients alive without a heart 
transplant or other cardiac surgery, at the end 
of the six-month follow-up and in whom heart 
failure was present since at least six months 
before levosimendan), the number of heart 
failure hospitalizations per patient was 1.3±1.0 
versus 0.4±0.7 (p<0.001); the number of days 
of hospitalization for heart failure per patient 
was 14.9±14.6 versus 3.1±7.6 (p<0.001); the 
percentage of patients hospitalized at least once 
was 81% before versus 29% after levosimendan 
(p<0.001).
Table VI Heart rate, systolic blood pressure, QTc, serum potassium and hemoglobin at 24 hours and at 5 days compared 
to baseline.
 Baseline 24 hours p 5 days p
Heart rate (beats/min) 86±18 85±16 p=0.150  83±15 p=0.086
Systolic blood pressure (mmHg) 104±17 100±16 p=0.009 101±17 p=0.079
QTc (ms) 425±48 430±48 p=0.100 427±42 p=0.747
Serum potassium (mmol/l) 4.4±0.7 4.0±0.4 p<0.001 4.2±0.5 p=0.057
Hemoglobin (g/dl) 12.7±1.9 12.2±1.7 p<0.001 12.2±1.8 p<0.001
Table VII Supraventricular arrhythmias (atrial fibrillation/flutter, or supraventricular tachycardia), nonsustained 
ventricular tachycardias, significant hypotensive episodes (systolic blood pressure <80 mmHg for >3 min) and angina 
during the first 24 hours after levosimendan and during the period between 24 hours after levosimendan and day 5, 
compared to the 24 hours before levosimendan.
 24h before 24h after p (24h after LeVO  From 24h after p (From 24h after
 LeVO LeVO vs. 24h before LeVO LeVO to day 5  LeVO today 5 vs.  
     24h before LeVO)
SVA (% of patients) 29% 27% p=0.371 30% p=0.999
NSVt (% of patients) 12% 10% p=0.772 8% p=0.227
SHE (% of patients) 10% 31% p<0.001 11% p=0.791
Angina (% of patients) 5% 1% p=0.125 3% p=0.687
LEVO: levosimendan; NSVT: nonsustained ventricular tachycardias; SHE: significant hypotension episodes; SVA: supraventricular arrhythmias.
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order to reduce the risk of bias in the participants. 
eight subjective and objective variables were 
used, which, when analyzed together, enabled 
a more accurate understanding of the patient’s 
response to treatment. the occurrence of serious 
adverse events was the chosen indicator of safety. 
to strengthen the latter parameter, we included 
not only serious adverse events considered to 
have a causal relationship with levosimendan, 
but also those for which the relation was 
undetermined. Data on readmissions for heart 
failure during a six-month period were used as a 
measure of medium-term outcome(1,6,22,23).
This study in the context of the literature 
on levosimendan. Other multicenter studies 
have assessed the efficacy and safety of 
levosimendan in patients with decompensated 
low output chronic heart failure. their primary 
endpoints consisted of the evaluation of changes 
in hemodynamic parameters at six(24) or 24 
hours(10,25) after the beginning of the infusion. 
In addition to being nonrandomized, our study 
differs from these works(10,24,25) by the fact that, 
like in ReVIVe(9), it had a clinical rather than 
a hemodynamic primary endpoint; taking into 
account the pharmacokinetics of levosimendan 
and its metabolites(7,8) we chose to evaluate this 
primary combined endpoint not only at 24 hours, 
but also at the end of a longer period of 5 days. 
the population included in our study is most 
comparable to those in LIDO and in ReVIVe 
in terms of baseline demographics, clinical 
characteristics and concomitant therapy.
Clinical effectiveness. We showed that in 
daily practice conditions a 24-hour infusion of 
levosimendan was clinically effective and safe in 
the majority of patients with acute systolic heart 
failure. these positive results were observed 
at 24 hours and were sustained at day 5, long 
after the end of the infusion. Our observations 
are consistent with those of the above-mentioned 
randomized studies(9,10,24,25). there was an improve -
ment in a number of meaningful clinical endpoints, 
including heart failure symptoms and signs and 
markers of renal function. the improvement in 
symptoms is important, since thus far there is 
little evidence that other inotropes can achieve 
this goal(8). In ReVIVe, LIDO and the study by 
Slawsky et al. (9,10,24), there was an improvement 
in heart failure symptoms with levosimendan. In 
the RuSSLAN(11) study, symptom improvement 
was not observed, but the patient population in 
in the trials received better medical care; the 
standard of care in a trial may not reasonably 
be expected in practice(19). In Desmond Julian’s 
opinion “we must be circumspect in translating 
trials into clinical practice”(19). this reinforces 
the role of observational studies.
Randomized studies of levosimendan in 
acute heart failure. Although objective evidence 
in favor of levosimendan has accumulated in 
recent years(6-8,10,11), some cooling in enthusiasm 
regarding this drug occurred after the pre sent- 
ation of neutral results on mortality, when 
levosimendan was compared with dobutamine 
in the SuRVIVe study(13). However, other 
recent trials showed that levosimendan was well 
tolerated in patients after an acute myocardial 
infarction(11), and in chronic decompensated heart 
failure(10), had a stronger hemodynamic effect 
than dobutamine(10) (and this effect, unlike with 
dobutamine, was not hampered by beta-blockers), 
induced a more marked and sustained decrease 
in BNP levels than dobutamine(13), improved 
clinical course(9), had a favorable impact on 
hospitalizations(9,10) and was cost-effective versus 
dobutamine(20) and, in LIDO and CASINO(9,12), 
when compared with dobutamine, and used 
in moderate doses, had a positive impact on 
prognosis. the european Society of Cardiology’s 
guidelines on acute and on chronic heart failure 
incorporate some of these findings(1,21). However, 
these developments have yet to be widely 
implemented in clinical practice. the purpose of 
our study was to determine whether the benefits 
demonstrated in randomized studies would 
translate into two outcomes that are important 
for physicians and their patients in day-to-day 
practice conditions: clinical improvement and 
absence of serious adverse events.
Primary endpoint. the recent european 
Society of Cardiology guidelines on acute 
heart failure(1) indicate that, together with an 
improvement in hemodynamic parameters, the 
immediate goals for the treatment of acute heart 
failure include improvement in symptoms(1) and 
a reduction in the clinical signs of heart failure(1). 
A favorable safety and tolerability profile is 
also essential for any treatment(1). Our primary 
endpoint evaluated these clinically relevant 
aspects in regard to levosimendan therapy. Given 
that our study was nonrandomized, an effort was 
made to define a rigorous method of classification 
while maintaining simplicity in clinical criteria in 
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than with dobutamine, in SuRVIVe) and was 
not reported in significant numbers in previous 
studies(10,11). Once again the high fixed loading 
dose and infusion rate of levosimendan in 
ReVIVe and SuRVIVe may have played a role. 
It thus seems advisable to avoid loading doses in 
patients with systolic blood pressure <90mmHg 
and to use initial low infusion rates that can be 
increased later if hypotension does not ensue 
and a stronger effect is needed. Monitoring of 
patients’ blood pressure and volume status during 
levosimendan therapy, and volume replacement 
as needed, are essential. Serum potassium 
monitoring is also warranted.
Hospitalizations. Hospital stay after 
levosimendan administration was brief, usually 
shorter than the 9.5 days mean duration of heart 
failure hospitalizations in Portugal(30). Hospital 
admissions represent about 75% of total 
expenditure on heart failure(1,31). therefore, the 
marked reduction in heart failure hospitalizations 
during the subsequent 6 months indicates that 
levosimendan can help decrease the total costs 
involved in the management of patients with heart 
failure who need inotropic support. this decline in 
hospitalizations is also compatible with a beneficial 
effect of levosimendan on the pathophysiology of 
heart failure, since it differs from the high rate of 
hospital readmissions usually observed after acute 
heart failure episodes(1,32). Since levosimendan 
improves hemodynamics(7,8,10,24,25) and diminishes 
neurohormonal activation(7-9,13,25,33), it may diminish 
necrosis and apoptosis during acute heart failure 
episodes. thus it would be conceivable that, by 
protecting the myocardium, a 24-hour infusion of 
levosimendan could have a favorable impact on 
new episodes of acute heart failure, and possibly 
mortality, during the following 6 months. this is 
similar to the observation that the administration 
of a thrombolytic drug during an acute myocardial 
infarction can influence 1-year prognosis(34).
Mortality. In our study, the rate of death or 
transplantation at 6 months was 29%, a value 
similar to the 26% mortality rate at 6 months 
observed in the levosimendan arm of LIDO, a 
study that showed superiority of levosimendan 
versus dobutamine in terms of prognosis(10).
Limitations. Our study has several limita-
t ions.
The small sample size calls for the confirmation 
of the results by a larger trial.
the fact that the study was neither blind nor 
RuSSLAN differed from that in our study since it 
included only post-myocardial infarction patients 
and the duration of the levosimendan infusion 
was limited to 6 hours.
Renal function. the improvement in renal 
function is also important since renal deterioration 
is associated with increased mortality(26). Contrary 
to our experience with levosimendan, other new 
therapies for acute heart failure, such as the 
vasodilator nesiritide, have a negative impact on 
renal function(27).
Safety. As in other studies(10,11,24,25), levosi-
mendan was overall well tolerated by our patients. 
Few presented serious adverse events.
Angina. It is important to note that, unlike 
with other inotropes(6), the incidence of angina 
did not increase during the initial 5-day 
follow-up. this is in agreement with published 
data showing no increase in the recurrence of 
myocardial ischemia with levosimendan(11).
Arrhythmias. In our study the percentage 
of patients presenting atrial fibrillation or 
ventricular tachycardias also did not increase 
during the first 5 days compared to baseline. 
Atrial fibrillation episodes occurred more 
frequently with levosimendan than with 
placebo in ReVIVe(9), and with dobutamine in 
SuRVIVe(13). Ventricular tachycardia was more 
frequent with levosimendan than with placebo in 
ReVIVe(9), but not more than with dobutamine 
in SuRVIVe(13). this discrepancy between our 
results and those of ReVIVe and SuRVIVe 
may be related to the higher infusion rates of 
levosimendan used in these two studies (0.2 μg/kg/
min as opposed to 0.1 μg/kg/min in PORtLAND). 
In fact our results were in agreement with what 
was expected taking into account the fact that 
intracellular calcium and cyclic-AMP did not 
increase with levosimendan(6-8) and the previous 
observation that there is no pro-arrhythmic effect 
associated with this drug(28,29).
Hypotension and hypokalemia. the 
most frequent adverse events in our study were 
hypotension and hypokalemia. these occurred 
most frequently during the first 24 hours after 
the initiation of levosimendan. Hypotension 
was probably related to vasodilatation and 
massive diuresis induced by levosimendan, 
and hypokalemia a consequence of the latter. 
Hypotension was also very frequent in REVIVE 
and SuRVIVe (more frequent with levosimendan 
than with placebo, in ReVIVe, but not more 
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controlled carries the risk that observations may, 
at least in part, be due to a placebo effect or to 
investigator bias. However, we believe our method-
ology helped to minimize this potential bias.
It could be argued that many patients admitted 
with acute heart failure improve with standard 
therapy. However the patients included in our 
study were judged by the investigators to need 
inotropic therapy precisely because they were not 
improving with standard therapy, i.e. iv diuretics 
or nitrates. Most of the improvement in the 
measured subjective and objective parameters 
occurred during the first 24 hours after the 
initiation of levosimendan (Table IV). At 24 hours 
there was no increase in the number of patients on 
iv diuretics and fewer patients were on iv nitrates 
compared to baseline. So the temporal relationship 
between clinical improvement and levosimendan 
administration is, in the present case, in favor of 
the existence of a causal relationship.
Concomitant inotropes. Since 25 (19%) 
patients were on concomitant dobutamine and/
or dopamine at baseline (Table III) it could 
be questioned whether the results observed 
at 24 hours and 5 days can be attributed to 
levosimendan alone or to the other inotropes. 
Several considerations are useful when analyzing 
this issue: 1 - the half-life of dobutamine is 
2.4±0.7 minutes and that of dopamine is 120 
minutes(35). 2 - the half-life of levosimendan is 
1.1±0.2 hours at a regimen of 0.05 μg/kg/min(36), 
which means that a steady state concentration 
is reached at 4 hours after the beginning of 
the infusion(8,37). 3 - Levosimendan has an 
active metabolite, OR-1896, with peak serum 
concentration occurring one to two days after 
the cessation of a 24-hour infusion(8); it has an 
elimination half-life of approximately 80 hours(8), 
allowing the pharmacologic effects to persist for 
approximately 1 week(8). 4 - In all but one of the 
16 (12%) patients in whom levosimendan was 
used to replace other inotropes, these agents 
were stopped 2-4 hours after the initiation of 
levosimendan. Considering points 1 and 2, the 
effects observed in these 15 patients at 24 hours 
and 5 days cannot plausibly be attributed to the 
inotropes that were replaced by levosimendan, 
since their pharmacological action had ended 
long before. the remaining patient maintained 
dopamine throughout the 5-day follow-up and 
reached the primary combined endpoint at 24 
hours and at day 5. 5 - As to the 9 (7%) patients 
in whom levosimendan was used in combination 
with other inotropes, 5 maintained the inotropes 
at 24 hours (three of whom reached the primary 
endpoint at 24 hours) and four were still taking 
inotropes at day 5, none of whom reached the 
primary endpoint at that time. to summarize, 
only four (4%) of the 104 patients reaching the 
primary endpoint at 24 hours, and one (1%) of 
the 102 that did the same at 5 days, were taking 
a concomitant inotrope at that point. We cannot 
exclude the possibility that, in these few patients, 
the results were due to the combination of the 
effects of levosimendan with those of the other 
concomitant inotropes. However, the percentage 
of patients reaching the primary endpoint who 
were under the effect of levosimendan and another 
inotrope is so small that it is hardly conceivable 
that the overall results of the study are not due to 
levosimendan and its metabolites.
CONCLUSIONS
Previous double-blind, randomized, control led 
studies showed that levosimendan had a positive 
impact in hemodynamics and clinical course, 
with a still unclear effect on prognosis(9-13,24,25). 
Our study shows that clinical efficacy and safety, 
seen when levosimendan was used at moderate 
doses in randomized studies, can be observed in 
day-to-day practice conditions, when the infusion 
regimens and the optional use of a loading dose 
of the drug are adapted to the patients’ condition. 
the fact that it was possible to administer 
levosimendan without invasive monitoring in 
the majority of patients shows that the use of the 
drug can be safely extended to centers with less 
extensive monitoring capabilities.
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